Endocrinology/Metabolism

Clinical trials for Endocrinology/Metabolism specialty

  • Status:  Currently enrolling

    Description:

    We hypothesize that the orally administered drug, bexagliflozin, will improve glycemic control in poorly regulated diabetic cats. The primary objective of this study is to determine if mean blood sugar and fructosamine concentrations decrease by ≥10% with administration of bexagliflozin over a two week period. The secondary objective is to determine if bexagliflozin is well tolerated by poorly regulated diabetic cats.

    Inclusion Criteria:

    Cats with unregulated diabetes mellitus based on history of persistent hyperglycemia(>250 mg/dl) and appropriate clinical signs, including polyuria, polydipsia and weight loss

    Exclusion Criteria:

    Cats with documented azotemia, elevated bilirubin, ALT >2.5x the upper limit of normal, diabetic ketoacidosis, urinary tract infection, use of corticosteroids within the past 8 weeks, heart disease requiring medication and uncontrolled hyperthyroidism based on preliminary laboratory testing

    Client benefits:

    The study will cover the costs of blood work and urine tests required for the study, blood pressure measurement, day boarding as well as the cost of the medication.  We will be teaching you how to monitor your cat's blood glucose levels at home with a hand held glucometer that will be loaned from our hospital for the duration of the study.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

  • Status:  Currently enrolling

    Description:

    Poor control of the glucose levels in diabetic dogs can alter how the drugs behave in the body, which can result in drug toxicities. The changes in blood proteins caused by diabetes can significantly affect the disposition of the many protein-bound drugs used in diabetic patients. This study will explore a model that will allow identification of changes in protein binding that will improve the safety of giving different medications to diabetic patients. This study has the potential to help diabetic dogs to receive appropriate medical care and have a better quality of life.

    Inclusion Criteria:

    Well diabetic adult dogs that weigh at least 3 kg (6.6 lbs) of any age and breed will be included in the study.

    Exclusion Criteria:

    Sick dogs, those receiving drugs known to be highly protein bound, and hypoalbuminemic dogs will not be included in the study.

    Client Benefits:

    The study entails having 2-3 teaspoons (12-15 ml) of blood drawn from your dog.  As an incentive, the study will cover the cost of a blood chemistry profile that would be performed as part of your dog's visit.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials office: clinicaltrials@tufts.edu